Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Key Inclusion Criteria: * Males and females, 18 to 70 years of age * Hepatitis C virus (HCV) genotype 1a or 1b * HCV-treatment naive * HCV RNA \>10,000 IU/mL at screening * HIV-1 infection (approximately 250 patients receiving highly active antiretroviral therapy \[HAART\], up to 50 patients not receiving HAART) * For patients receiving HAART, HIV RNA must be below \<40 copies/mL at screening and must be \<400 copies/ml for at least 6 months prior to screening Key Exclusion Criteria: * Patients receiving HAART who first initiated antiretroviral therapy within the last 6 months of Day 1 * Patients receiving HAART who have changed their antiretroviral regimen due to safety or efficacy associated to HIV treatment within the last 3 months prior to Day 1. However, if changes are required to a patient's HAART regimen to meet the requirements of the protocol, these changes are allowed at the screening visit. The patient should wait a minimum of 1 month prior to Day 1 after a repeat of HIV viral load has been confirmed, \<40 copies/ mL * Use of prohibited HAART regimens within 1 month of Day 1 and throughout the treatment period of the trial (patients receiving HAART who have changed their antiretroviral regimen to initiate any HCV treatment within 6 weeks prior to Day 1) * Laboratory values: 1. Neutrophil count \<1500 cells/μL (\<1200 cells/ μL for Blacks) 2. Platelet count \<90,000 cells/μL 3. Hemoglobin ≤12 g/dL for females, hemoglobin ≤13 g/dL for males 4. Total bilirubin ≥34 μmol/L (or ≥2 mg/dL) unless a patient has a documented history of Gilbert's disease or antiretroviral regimen contains atazanavir 5. Alanine aminotransferase ≥5\*upper limit of normal